PTPRC and cancer: When using the same siRNAs and reagents for transfection of the CD133-expressing cancer cell line Weri-RB1 or the CD45-expressing haematopoietic cell line K562, there was a significant knockdown of the respective target protein (P ≤ 0.001), proving the functionality of siRNAs and reagents (Fig. 2a,b).